-
The traditional Chinese medicine sector has changed! Kangyuan Pharmaceutical rose more than 6%, and Dong Ejiao rose nearly 5
Time of Update: 2023-02-01
News on January 12, the traditional Chinese medicine sector changed, in terms of individual stocks, Kangyuan Pharmaceutical rose by more than 6%, and Dong'a Jiao rose by nearly 5%, in addition, Jianmin Group, Pian Zixi, Zhongsheng Pharmaceutical, etc.
-
How much do you know about pathogenic microorganisms
Time of Update: 2022-09-16
In addition to the bacteria and viruses that we often hear about the microorganisms that cause infection, there are fungi, mycoplasma, chlamydia, parasites, prions, etc.
In addition to the bacteria and viruses that we often hear about the microorganisms that cause infection, there are fungi, mycoplasma, chlamydia, parasites, prions, etc.
-
A&R: Identification of Mitofusin 1 and complement component 1q subcomponent binding proteins as mitochondrial targets in systemic lupus erythematosus
Time of Update: 2022-08-16
Leave a comment here Purpose : Mitochondria exhibit various bacterial characteristics, such as a double-stranded genome with hypomethylated CpG islands, formylated proteins, and cardiolipin-containing membranes .
Leave a comment here Purpose : Mitochondria exhibit various bacterial characteristics, such as a double-stranded genome with hypomethylated CpG islands, formylated proteins, and cardiolipin-containing membranes .
-
Under the intensified competition in the PD-1 market, domestic pharmaceutical companies are speeding up going overseas
Time of Update: 2021-12-07
In fact, in the same year, Livzonumab had already licensed the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeting Immune cytokines (PD-1 ICs), and authorized LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China .
-
Multinational companies take measures to improve medical service capabilities to meet patient needs
Time of Update: 2021-12-07
Huang Jingxuan, head of GSK China’s core prescription drug business department, revealed: “In addition to epilepsy, we will also invest more in the field of bipolar disorder, including doctor education, to improve the level of disease diagnosis and treatment .
-
SART1 anti-hepatitis B virus new mechanism is solved
Time of Update: 2021-08-01
Spliceosome-associated factor 1 (SART1) inhibits hepatitis B virus (HBV) new mechanism: on the one hand, SART1 regulates the expression of interferon downstream genes (ISGs); on the other hand, SART1 inhibits it by binding to the hepatocyte nuclear factor 4 (HNF4α) promoter Transcription, and then down-regulate the transcription of hepatitis B virus small chromosome cccDNA .
-
It's a real move! Antitrust guidelines in the field of API are in place
Time of Update: 2020-11-13
in order to promote the healthy development of the API industry, maintain the order of competition in the API market, protect the interests of consumers and the public interest, prevent and stop monopoly in the field of API, and promote scientific and effective anti-monopoly supervision.
